Frontlight ResearchEarly access
CompletedPhase 4
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicentre clinical trial
Key facts
- Who runs it
- KRKA tovarna zdravil d.d. Novo mesto
- Where
- Poland4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 38 people enrolled
- Started
- 21 May 2025
- Ended
- 17 Sept 2025
- Type of study
- Interventional
- Record updated
- 21 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 39 criteriaShow less
Who can take part
- Female or male patients, aged ≥40 years
- Patients diagnosed with primary osteoarthritis with disease severity grade III or IV according to the Kellgren-Lawrence classification
- Average intensity of pain in investigated knee joint ≤6 in last 24h on numeric rating scale (NRS)
- Ultrasound examination of investigated knee, that confirms presence of synovial fluid in sufficient amount for withdrawal of at least 1ml of synovial fluid
- Patients who have been provided with information about the trial and have voluntarily signed the informed consent
- Patients who have signed the consent for collection, analysis and processing of personal data, that will be collected during this clinical trial for the purpose of statistical analysis and final report of this clinical trial
- Patients with ability to adhere to the trial protocol according to the investigator’s judgement
- Successfull arthrocentesis of the investigated knee on Visit 2 with at least 1ml of obtained synovial fluid in which no visible blood is present
Who cannot take part
- Medications that could confound the evaluation of pain relief (anti-epileptics, benzodiazepines, pregabalin and antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs) are allowed if dose is stable for > 3 months before Visit 1)
- Medications that may increase the risk of nephrotoxicity: cyclosporin, tacrolimus
- Medications that may increase the risk of hepatotoxicity and hematoxicity: myelotoxic drugs
- Known presence or history within the past 2 years of gastrointestinal ulcer, gastrointestinal bleeding, or gastrointestinal complaint related to previous NSAID treatment or congestive or atrophic gastritis
- Any serious acute disease with or without subsequent hospitalization within 30 days prior to Visit 1, such as: severe local or systemic infection, exacerbation or uncontrolled phase of a chronic disease, major trauma, major surgery (including planned major surgery during the trial involvement), COVID-19, as well as post-COVID-19/long COVID-19 syndromes diagnosed
- Patient is currently participating in another clinical trial or has participated in another clinical trial within 30 days prior to the Visit 1
- Intra-articular treatment with corticosteroids or hyaluronic acid within 6 months prior to Visit 1
- Current treatment or treatment within 3 months prior to Visit 1 with corticosteroids in any of pharmaceutical form or indomethacin
- Disturbances of bone marrow function (e.g., after treatment with cytostatic medicinal products) or haematopoietic disorders
- Medications that may interfere with pain perception or inflammation: all analgesics other than TIMP and RM, all antihistamines and corticosteroids in any of pharmaceutical form
- Active chronic painful conditions apart from osteoarthritis
- Medications that may increase the risk of bleeding such as: anticoagulants, antiplatelets (except low dose aspirin for cardioprotection), thrombolytics
- Inflammatory bowel disease
- Haemodynamically unstable heart failure after acute myocardial infarction, congestive heart failure, severe heart failure (NYHA class III and IV) or postoperative period of ≤ 3 months after coronary bypass grafting
- History of surgical treatment of the investigated knee joint
- Severe liver problems such as cholestasis or biliary obstructive disorders or hepatic encephalopathy or severe hepatic impairment or hepatic encephalopathy or any other severe liver disease
- Any serious clinical state that could affect patient safety, protocol compliance or treatment adherence, or have an impact on patient’s short-term survival rate, such as: advanced malignant disease or any other life-threatening illness, excessive chronic alcohol consumption (defined as ≥15 units per week for men or ≥8 units per week for women), heavy smoking (more than 20 cigarettes/day), medicine abuse or addiction, psychoactive substance abuse or addiction, chronic infection with HIV and/or HBV and/or HCV, uncontrolled seizures, uncontrolled psychiatric conditions
- Hypersensitivity or intolerance to naproxen or paracetamol or any excipient of the Tested Investigational Medicinal Product (TIMP) or placebo, rescue medicine (RM) or to salicylates and other non–steroidal anti-inflammatory drug (NSAID) and anti-rheumatic drugs manifested as bronchial asthma, urticaria and rhinitis
- Bleeding disorders (e.g., haemophilia or other blood clotting or haemostatic disorder, cerebrovascular bleeding within last 6 months)
- Medications whose plasma concentration will be affected: probenecid, methotrexate (reduced clearance), phenytoin, chloramphenicol
- Renal impairment (GFR <45 mL/min/1.73 m2) , progressive kidney disease, confirmed hyperkalemia (above max. reference value) that is clinically significant according to ivestigator's opinion
- Glucose-6-phosphate dehydrogenase deficiency, acute intermittent hepatic porphyria
- Significant anaemia with haemoglobin ≤80 g/L
- Significant thrombocytopenia with platelet count less than < 50x109/L
- Serum AST and/or ALT and/or total bilirubin of ≥3x ULN
- Rheumatoid arthritis based on physical examination and laboratory data
- Any acute cardiovascular or cerebrovascular event within the last six months
- Pregnancy or lactation
- Female of childbearing potential without highly effective contraception (according to the Recommendations related to contraception and pregnancy testing in clinical trials ) or female planning to become pregnant during the trial
- Patient is a member of the research team and is actively involved in the trial conduct as such
- Patient refuses to cooperate with the investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the effect of naproxen sodium therapy on the synovial fluid (SF) concentration of Interleukin-6 (IL-6), after 14 days of treatment in comparison to placebo in patients with knee osteoarthritis.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial
- Record updated
- 21 October 2025